The race to catch KRAS, pancreatic cancer’s ‘greasy ball,’ and create the most promising drug in decades

The race to catch KRAS, pancreatic cancer’s ‘greasy ball,’ and create the most promising drug in decades

Daraxonrasib, a pancreatic cancer drug from Revolution Medicines, is showing unprecedented success. For patients like Leanna Stokes, survival time doubled.

StockWatch: Revolution’s Phase III Pancreatic Cancer Data Dazzles Investors, Analysts

Pancreatic cancer is one of the most difficult cancers to treat, with an overall five-year survival rate of 13%, according to the American Cancer Society, stretching from 3% for metastatic (Stage 4) to 44% for localized (Stages 1 and 2). Dismal odds such as these explain the enthusiastic response of investors when Revolution Medicine (NASDAQ: RVMD), a developer of RAS-addicted cancer therapies, announced dazzling data from its Phase III RASolute…